HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilars name, notification debates rage on in the US, but costs still 'elephant in the room'

This article was originally published in SRA

Executive Summary

Whatever the ultimate outcome turns out to be for the debates in the US over the naming of biosimilars or prescriber notification of interchangeable products, the medicines are bound to be "among the most deeply analyzed and predictable" drugs to hit the US market, said Dr Emily Shacter, a former Food and Drug Administration official and now an independent consultant with ThinkFDA.

Advertisement
Advertisement
UsernamePublicRestriction

Register

PS117713

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel